Image pharmaphorum Editor Debates & Insight Sponsored From promise to practice: immuno-oncology in action – the ne... Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. Debates & Insight Sponsored Available on demand: Patient centricity 101 – How to create ... Debates & Insight Sponsored Available on demand: Why the success of your HTA will rely o... Debates & Insight Sponsored Available on demand – Predicting success: How advanced analy... Load more results
Debates & Insight Sponsored From promise to practice: immuno-oncology in action – the ne... Immuno-oncology therapies that harness the body's own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment.
News MSD takes a $400m bite of SciBrunch's KRAS drug MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
